Cargando...
Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy?
Tyrosine kinase inhibitors are de facto the most commonly used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). After the first era in which targeted agents were compared with placebo and interferon-α, a new phase has started in recent years characterized by head-t...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4026069/ https://ncbi.nlm.nih.gov/pubmed/24556857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.28161 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|